1334922-19-8

Basic information

• Product Name: 1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone
• Synonyms: 1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone
• CAS NO: 1334922-19-8
• Molecular Weight: 270.328
• Mol File: 1334922-19-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone(1334922-19-8)
• EPA Substance Registry System: 1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone(1334922-19-8)

Safety Data

• Hazardous Substances Data: 1334922-19-8(Hazardous Substances Data)

Upstream product

• 83759-88-0 1-(4-amino-2,6 dimethylphenyl)ethanone 
• 35887-71-9 1-(4-chloro-2,6-dimethylphenyl)ethanone 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 1334922-22-3 2-bromo-1-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone 
• 1334921-09-3 2-fluoro-N-{4-[4-(4-methoxyphenoxy)-2,6-dimethylphenyl]-thiazol-2-yl}pyridine-4-carboxamide 
• 1334921-03-7 N-{4-[4-(4-methoxyphenoxy)-2,6-dimethylphenyl]thiazol-2-yl}pyridine-4-carboxamide 
• 1439935-83-7 N-{4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl}acetamide 
• 1439935-82-6 N-{5-bromo-4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl}isonicotinamide 
• 1439935-85-9 5-bromo-4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-amine 
• 1439935-84-8 N-{5-bromo-4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl}acetamide 

Relevant articles and documents

Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: Optimization of in vitro potencies and pharmacokinetic properties

A series of 4-aryl-N-arylcarbonyl-2-aminothiazoles of scaffold 4 was designed and synthesized as Hec1/Nek2 inhibitors. Structural optimization of 4 led to compound 32 bearing C-4′ 4-methoxyphenoxy and 4-(o-fluoropyridyl) carbonyl groups that showed low nanomolar in vitro antiproliferative activity (IC50: 16.3-42.7 nM), high intravenous AUC (64.9 μM·h, 2.0 mg/kg) in SD rats, and significant in vivo antitumor activity (T/C = 32%, 20 mg/kg, IV) in mice bearing human MDA-MB-231 xenografts. Cell responses resulting from Hec1/Nek2 inhibition were observed in cells treated with 32, including a reduced level of Hec1 coimmunoprecipitated with Nek2, degradation of Nek2, mitotic abnormalities, and apoptosis. Compound 32 showed selectivity toward cancer cells over normal phenotype cells and was inactive in a [ 3H]astemizole competitive binding assay for hERG liability screening. Therefore, 32 is as a good lead toward the discovery of a preclinical candidate targeting Hec1/Nek2 interaction.

Modulators Of HEC1 Activity And Methods Therefor

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.